BAJAJ BROKING
Dr. Reddy’s Laboratories delivered a strong Q2 FY24-25, showcasing substantial revenue growth with consolidated revenue reaching ₹80,162 million. However, profit after tax saw a slight decline. Explore detailed insights and segment breakdown.
Dr. Reddy’s Laboratories reported consolidated revenue of ₹80,162 million for Q2 FY24-25, a year-over-year increase of 17% and a quarter-over-quarter growth of 4%. Despite higher costs, the gross profit margin remained strong, supporting Dr. Reddy's growth across its generics and emerging markets segments.
The net profit after tax reached ₹13,415 million, a 9% decline YoY, mainly due to one-time expenses, including acquisition-related costs and tax adjustments. This stable financial performance, combined with strategic investments in research and partnerships, underscores Dr. Reddy’s ongoing commitment to operational efficiency and expansion into emerging markets.
Dr. Reddy’s Q2 results exceeded industry expectations, with a substantial increase in revenue from its generics segment, especially in North America and emerging markets. This growth aligns with the sector’s robust demand for generic drugs, while slight declines in profit were anticipated due to higher SG&A and R&D investments.
G V Prasad, Co-Chairman & MD of Dr. Reddy’s, noted, "We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell® and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation."
Metric | Q2 FY24-25 | Q1 FY24-25 | Q2 FY23-24 |
Revenue (₹ million) | 80,162 | 76,727 | 68,802 |
Gross Profit (₹ million) | 47,769 | 46,344 | 40,368 |
EBITDA (₹ million) | 22,803 | 21,599 | 21,813 |
PAT (₹ million) | 13,415 | 13,920 | 14,800 |
EPS (₹) | 15.07 | 16.72 | 17.80 |
Selling & Administrative Expenses | 23,007 | 22,691 | 18,795 |
R&D Expenses (₹ million) | 7,271 | 6,193 | 5,447 |
Check out Dr Reddy's Lab's past performances in previous quarters and financial years.
Dr. Reddy’s Q2 results for FY24-25 demonstrate a solid performance with significant revenue growth across core segments. Despite challenges from rising costs and tax adjustments, the company has maintained a stable profit margin, underscoring its resilience and strategic focus. With new acquisitions, partnerships, and a strong presence in emerging markets, Dr. Reddy’s is well-positioned for sustained growth in the coming quarters.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Gold Rate Today | 2 January 2025 | Gold Price in India
02 Jan, 2025 | 40 Min. read
Lloyds Metals Reports Record Iron Ore Output, Stock Hits 52-Week High
02 Jan, 2025 | 2 Min. read
Commercial Property Insurance Premiums Surge by 80% from January 2025
02 Jan, 2025 | 2 Min. read
Cabinet Increases PMFBY Allocation to ₹69,515 Crore for 2025-26
02 Jan, 2025 | 2 Min. read
How to Apply for Fabtech Technologies Cleanrooms IPO?
02 Jan, 2025 | 1 Min. read
Fabtech Technologies Cleanrooms IPO
02 Jan, 2025 | 3 Min. read
HDFC Life Faces ₹270.58 Crore GST Demand, Plans to Appeal
02 Jan, 2025 | 2 Min. read
T-Test: Definition, Types, How To Use and Examples
02 Jan, 2025 | 4 Min. read
Z-Test: Definition, Uses in Statistics, and Example
02 Jan, 2025 | 4 Min. read
Piramal Enterprises Invests ₹1,000 Crore in Piramal Capital via Rights Issue
01 Jan, 2025 | 2 Min. read
Kalpataru Projects Secures ₹1,011-Crore Orders Across Key Sectors
01 Jan, 2025 | 2 Min. read
Transformer & Rectifier to Consider Bonus Issue on 8 January
01 Jan, 2025 | 2 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading